MedTrace Logo

Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis

NCT05617664 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-08-03

No results posted yet for this study

Summary

Investigators will study the efficacy and safety of mirabegron25 in treatment of primary nocturnal enuresis in comparison to oral desmopressin 120 mcg and behavioral therapy

Conditions

  • Nocturnal Enuresis

Interventions

DRUG

desmopressin 120 mcg oral tablets

treatment for three months then will stop

DRUG

Mirabegron 25 MG Oral Tablet, Extended Release

treatment for three months then will stop

BEHAVIORAL

behavioral therapy alone

no medications will be given to the patient

Sponsors & Collaborators

  • Benha University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-23
Primary Completion
2023-09-30
Completion
2023-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05617664 on ClinicalTrials.gov